Find Jobs
Find Jobs Near You – Available Work in Your Location
Skip to job details
A
Arvinas
Senior Medical Director Clinical Development Neuroscience
Career Insights for Medical Director
See where this job fits in the broader career landscape. Knowing your career path helps you see what's possible from here.
Scorecard
Based on Connecticut data
Review key factors to help you decide if this role fits your goals. How is this calculated?
What they do
A Medical Director directs and manages a medical practice, clinic, lab or public health program. Organizes and manages of staff physicians, policy implementation, and ensures that standards for medical care are communicated and maintained.
$254,043 / year median in Connecticut
+9% projected growth
Job Description
Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC® Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC® targeted protein degraders, that are designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including ARV-102, targeting LRRK2 for neurodegenerative diseases; ARV-806, targeting
KRAS G12D
for mutated cancers, including pancreatic, colorectal, and non-small cell lung cancers; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; ARV-027, targeting the polyglutamine-expanded androgen receptor, or polyQ-AR, in skeletal muscle; and vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastaticER+/HER2
- breast cancer. On August 8th 2025, the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for vepdegestrant
- an investigational, orally bioavailable PROTAC estrogen receptor degrader
- for its use as a monotherapy in the treatment of adults with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2
- , ESR1-mutated advanced or metastatic breast cancer previously treated with endocrine-based therapy.
- to improve the lives of patients with serious diseases by pioneering therapies created with our revolutionary PROTAC® protein degradation platform. We're really excited about the work we're doing inside and outside of Arvinas, and think you will be, too. But don't just take our word for it
- learn more about life at Arvinas and what employees have to say.